Company News: Page (1) of 1 - 03/08/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Gemphire to Present at Two Investor Conferences

(March 08, 2018)

LIVONIA, Mich., March 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that management will be making presentations at the 30th Annual ROTH Conference and the H.C. Wainwright 2nd Annual NASH Investor Conference.

Presentation Details

30th Annual ROTH Conference
Date:


Time:
Panel:
Panelist:
Location:
     Tuesday, March 13
7am Pacific Time/10am Eastern Time
It Is Not a Myth, It Is Real:  Pediatric NASH
Seth Reno, Chief Commercial Officer
Ritz Carlton, Laguna Niguel, California
   
Date:
Time:
Panel:
Panelist:
Location:
 Tuesday, March 13
8am Pacific Time/11am Eastern Time
Love Your Liver, Love Your Heart:  Cardio-Metabolic Molecules
Steve Gullans, Ph.D., Interim Chief Executive Officer
Ritz Carlton, Laguna Niguel, California
   
H.C. Wainwright 2nd Annual NASH Investor Conference
Date:
Time:
Presenter:
Location:
Webcast:
 Monday, March 19
8:40am Eastern Time
Steve Gullans, Ph.D., Interim Chief Executive Officer
St. Regis Hotel, New York City
http://wsw.com/webcast/hcw3/gemp/
   

About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH.  The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors.  Gemphire’s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, including FH and ASCVD, SHTG and NASH/NAFLD.  Two trials supporting hypercholesterolemia have been completed under NCT02722408 and NCT02634151.  Gemphire has completed recruitment for a clinical trial for SHTG under NCT02944383, and has initiated separate trials for adult NASH and pediatric NAFLD. Please visit www.gemphire.com for more information.

Contact:
Andrew McDonald, Ph.D.
LifeSci Advisors, LLC
(646) 597-6987

Jeff Mathiesen, CFO
Gemphire Therapeutics Inc.
(734)-245-1700


Page: 1


Related Keywords:

-->

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved